What Amlodipine-Teva treats: Main Uses and Benefits

The therapeutic role of Amlodipine is recognized in the management of key cardiovascular issues. This medication is commonly used for managing Systemic Arterial Hypertension (high blood pressure), and is applied to help manage symptoms related to chest discomfort, including Chronic Stable Angina and Vasospastic Angina.

The main benefit provided to the patient is sustained blood pressure control, which is considered relevant for supporting general well-being during periods of heightened physiological stress, and may assist in managing conditions linked to organ-specific functional stress. When managing chest discomfort, the medicine supports the reduction of the frequency and intensity of recurrent pain episodes, which assists with maintaining functional stability and contributes to improved comfort during daily functioning. It is also considered relevant for long-term supportive management in conditions marked by increased physiological stress, such as Coronary Artery Disease (CAD).

“Amlodipine is relevant in contexts marked by increased discomfort or tension, providing support that helps ease the overall symptom burden.”

---

Quick Fact: Supportive Relief for Recurrent Chest Discomfort

---

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults are eligible for all labeled uses, including hypertension and chronic forms of angina.
• Children and adolescents (6 to 17 years) are approved for the treatment of hypertension only.

Populations for whom use is contraindicated:

• Patients with known hypersensitivity to Amlodipine, other dihydropyridine derivatives, or any component of the tablet.
• Patients experiencing severe hypotension, a state of shock (including cardiogenic shock), or those with an obstruction of the left ventricular outflow tract (e.g., high-grade aortic stenosis).
• Use is prohibited in patients with haemodynamically unstable heart failure following an acute myocardial infarction.

Condition-specific eligibility rules:

• In patients with hepatic impairment, use is restricted and must be initiated at the lower end of the dosing range, proceeding with caution.
• For renal impairment, normal dosage is generally recommended, as Amlodipine pharmacokinetics are not significantly altered by kidney function.

Age and Reproductive Status:

• Use is not established in children under 6 years of age.
• In older adults, initiation of dosage requires caution.
• The safety of use during pregnancy is not established; use is only recommended when the maternal condition's risk is greater than the potential risk to the fetus. Amlodipine is excreted in human milk; a decision on continuing therapy must weigh the benefits against the unknown effects on the infant.

Interactions with other medicines and products

Property	Description (Strictly Regulatory)
Medicinal product categories with documented interactions:	CYP3A4 inhibitors and inducers; other antihypertensive agents; immunosuppressants; the lipid-lowering agent Simvastatin.
Mechanistic basis of interactions (only if stated in label):	Pharmacokinetic interaction (CYP3A4 enzyme modulation); Pharmacodynamic interaction (additive blood pressure lowering); Increased exposure of co-administered drugs.
Timing-based interaction rules (if applicable):	No mandatory timing separation is required for routine co-administration of medicinal products. Activated charcoal significantly decreases Amlodipine absorption (relevant for overdose).
Population-specific interaction notes (if applicable):	Hepatic Impairment: The severity of CYP3A4 inhibitor interactions may be heightened in this population due to already reduced drug clearance.

---

Interaction-related restrictions and statements

Category	Statement (Strictly Regulatory)
Exposure Modification Restriction	Co-administration with Simvastatin formally requires that the Simvastatin dose must not exceed 20 mg daily due to increased Simvastatin exposure.
Food and Herbal	Grapefruit or Grapefruit Juice consumption is officially not recommended due to the potential for increased Amlodipine systemic exposure.
Exposure Alteration	Strong or moderate CYP3A4 inhibitors (e.g., Ketoconazole, Diltiazem) are documented to increase Amlodipine systemic exposure. Conversely, CYP3A4 inducers may reduce Amlodipine concentration.
Co-administered Drug Levels	Co-administration may increase the blood levels of the immunosuppressants Tacrolimus and Ciclosporine.

---

The overall interaction structure is defined by its susceptibility to CYP3A4 enzyme modulation, which necessitates formal regulatory restrictions on the dose of Simvastatin and advisory restrictions regarding consumption of grapefruit products and enzyme inducers. The official profile also includes pharmacodynamic statements outlining the additive blood pressure lowering effect when combined with other cardiovascular medicines.

Molecular Blockade of Voltage-Gated Calcium Channels

Amlodipine-Teva's action begins with the selective inhibition of L-type calcium channels ( Cav1.2) in the arterial smooth muscle cell membrane. By binding to these channels, the drug blocks the critical influx of calcium ions, which is the required molecular trigger for muscle contraction. This mechanism interrupts the cellular signaling sequence that regulates arterial smooth muscle contraction.

---

Systemic Cascade to Reduce Vascular Resistance

The cellular effect of calcium channel blockade initiates a cascade leading to vascular smooth muscle relaxation (vasodilation) throughout the peripheral arterial bed. This physical widening of the peripheral arteries reduces the Total Peripheral Resistance (Afterload), which is the systemic hydraulic load placed on the heart. This systemic adjustment modifies the dynamics within the body’s pressure regulatory pathways.

---

Kinetic Selectivity and Afterload Modulation

The drug exhibits a characteristic slow rate of association and dissociation with its target, resulting in a sustained channel inhibition that defines the duration of the physiological effect. Its vascular selectivity causes the mechanism to focus primarily on reducing afterload by modulating arterial muscle tone, with a lower functional impact on the heart’s intrinsic contractility.

How to Use Amlodipine-Teva

Amlodipine-Teva is supplied as an oral tablet and is administered using a standardized protocol for chronic management. The medicine is taken once daily, a frequency established to maintain stable systemic concentrations. The tablets are intended to be swallowed whole and can be ingested independently of meals (with or without food).

Standard Labeled Dosage and Administration

The typical adult use pattern begins with an initial dose of 5 mg once daily for both arterial hypertension and chronic stable angina. The maximum recommended daily dose for adults is 10 mg. Dose adjustments, known as titration, must be made incrementally and should only occur after a period of 7 to 14 days to allow for the full therapeutic effect of the current dose to be assessed.

Population Group	Initial Dose	Maximum Dose	Special Constraint
Adults	5 mg once daily	10 mg once daily	7-14 day minimum titration interval
Older Adults	2.5 mg once daily	10 mg once daily	2.5 mg starting dose recommended
Hepatic Impairment	2.5 mg once daily	10 mg once daily	Slower titration is advised
Pediatric (6-17 years)	2.5 mg once daily	5 mg once daily	Maximum daily dose limited to 5 mg

Procedural Administration Principle

If a dose is missed, the instruction is to take it as soon as possible, unless it is almost time for the next scheduled dose. In such a scenario, the missed dose should be skipped entirely, and the regular schedule resumed. It is an explicit instruction that a double dose must not be taken to compensate for a missed one.

Amlodipine, a calcium channel blocker, has been the subject of extensive long-term clinical trials evaluating its effectiveness as a treatment for hypertension (high blood pressure) and coronary artery disease (CAD).

Core Clinical Outcomes

Evidence from major, large-scale studies has established that amlodipine-based therapy is comparable to other guideline-recommended first-line antihypertensive agents, such as thiazide diuretics and ACE inhibitors, in reducing the risk of major cardiovascular events.

• ALLHAT Trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial): This trial found no significant difference between amlodipine and a thiazide diuretic (chlorthalidone) in the primary outcome, which was a combination of fatal coronary artery disease and nonfatal myocardial infarction. It confirmed amlodipine's role in preventing the combined risk of stroke and myocardial infarction.
• ASCOT Trial (Anglo-Scandinavian Cardiac Outcomes Trial): The blood pressure-lowering arm of this trial demonstrated that an amlodipine-based regimen was associated with better outcomes for all-cause mortality and stroke compared to an atenolol-based regimen in high-risk patients.

Safety and Tolerability Profile

Clinical data consistently report that amlodipine is a generally well-tolerated medication. The most frequently observed side effect in trials is peripheral edema (swelling of the ankles or feet). This effect is related to the drug's mechanism of relaxing blood vessels and is often dose-dependent.

Side Effect (Most Common)	Incidence in Trials
Peripheral Edema	Frequently observed
Headache	Common
Flushing	Common

In patients with coronary artery disease and no evidence of heart failure, studies have shown that using amlodipine may help reduce the risk of hospitalization for angina and the need for coronary revascularization procedures. Amlodipine is recognized for its long-acting profile, providing 24-hour blood pressure control with a single daily dose.

Common questions about Amlodipine-Teva (FAQ)

---

Q: Does Amlodipine-Teva treat heart failure?

According to official product information, Amlodipine-Teva is not listed as a primary treatment for heart failure alone. Its indicated uses are for treating high blood pressure (hypertension) and a type of chest pain called chronic stable angina pectoris or Prinzmetal's angina. Regulatory documents mention that Amlodipine-Teva is not a primary treatment for heart failure, though it may be used as supportive therapy alongside other specific treatments in certain clinical contexts.

---

Q: Can I drink grapefruit juice while taking Amlodipine-Teva?

Official product information advises against the consumption of grapefruit or grapefruit juice while taking this medication. This is because grapefruit can lead to an increase in the levels of Amlodipine in the body, which could potentially cause an unintended drop in blood pressure. This substance is cited in regulatory documents as a known interaction, and official sources recommend avoiding it.

---

Q: What is Amlodipine-Teva used for?

Amlodipine-Teva is officially used to treat two main conditions. The first is high blood pressure, also known as hypertension. The second is a specific type of chest pain caused by reduced blood flow to the heart muscle, called chronic stable angina pectoris or the less common Prinzmetal's angina. This medicine belongs to a class of drugs known as calcium channel blockers.

---

Q: Is Amlodipine-Teva an ACE inhibitor?

No, Amlodipine-Teva is not an ACE inhibitor. Official information shows it belongs to a group of medicines called calcium channel blockers. It works by relaxing and widening the blood vessels, which helps blood flow more easily. ACE inhibitors work through a different mechanism on the body's enzyme systems.

---

Q: Does Amlodipine-Teva help with chest pain?

Yes, Amlodipine-Teva is indicated for the treatment of certain types of chest pain. It is officially used for treating chronic stable angina pectoris and Prinzmetal's angina, which is sometimes called variant angina. The mechanism of widening the arteries is intended to increase blood flow and oxygen to the heart muscle, which is the goal of treating angina.

---

How to Store and Dispose of Amlodipine-Teva

The required storage and disposal instructions for Amlodipine tablets are strictly defined by regulatory labeling.

---

Storage Conditions

Amlodipine tablets must be maintained at controlled room temperature, which is defined between 20 C and 25 C (68 F and 77 F). The product must be stored in the original container, which should be a tight, light-resistant container, and the cap must be kept tightly closed.

Crucially, the medication must be stored out of the sight and reach of children in a secured location.

Disposal Instructions

Unused or expired tablets should not be flushed down the toilet or discarded into wastewater. The preferred disposal method is returning the product to an official drug take-back program. If a take-back program is unavailable, the alternative procedure is mixing the tablets with an unappealing substance, sealing the mixture in a bag, and discarding it in the household trash.